¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"primary antibody response"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • evoked response
    À¯¹ß¹ÝÀÀ
  • evoked response audiometry
    À¯¹ß¹ÝÀÀû·Â°Ë»ç
  • frequency response curve
    Á֯ļö¹ÝÀÀ°î¼±
  • galvanic skin response
    Àü±âÇǺιÝÀÀ
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀû·Â°Ë»ç
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
  • inverse response
    ¿ª¹ÝÀÀ
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • inert response
    ºÒȰ¼º¹ÝÀÀ
  • inflammatory response
    ¿°Áõ¹ÝÀÀ
  • idiosyncratic drug response
    ƯÀ̾๰¹ÝÀÀ
  • inspiratory triggering response time
    µé¼ûÀ¯¹ß¹ÝÀÀ½Ã°£, Èí±âÀ¯¹ß¹ÝÀÀ½Ã°£
  • late asthmatic response
    ¸¸±âõ½Ä¹ÝÀÀ, Èıâõ½Ä¹ÝÀÀ
  • lytic response
    ¿ëÇØ¹ÝÀÀ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • primary cholestatic liver disease
    ÀÏÂ÷¾µ°³ÁóÁ¤Ã¼°£Áúȯ, ÀÏÂ÷´ãÁóÁ¤Ã¼°£Áúȯ
  • primary irritant dermatitis
    ¿ø¹ßÀÚ±ØÇǺο°
  • primary infection
    ÀÏÂ÷°¨¿°
  • primary
    ¿ø¹ß-, ÀÏÂ÷-
  • primary polydipsia
    ¿ø¹ß¼º´ÙÀ½Áõ, ÀÏÂ÷Àû´ÙÀ½Áõ, ¿ø¹ß¼º´ÙÀ½´Ù°¥Áõ, ÀÏÂ÷Àû´ÙÀ½´Ù°¥Áõ
  • spontaneous primary peritonitis
    ¿ø¹ßº¹¸·¿°, ÀÏÂ÷º¹¸·¿°, ¿ø¹ß¹è¸·¿°, ÀÏÂ÷¹è¸·¿°
  • primary stage
    Ãʱâ
  • primary suture
    ÀÏÂ÷ºÀÇÕ
  • occult primary tumor
    Àẹ¿ø¹ßÁ¾¾ç
  • antibody
    Ç×ü
  • anti-double stranded deoxyribonucleic acid antib antibody
    Ç×ÀÌÁß°¡´Úµð¿£¿¡ÀÌÇ×ü
  • anti-dsDNA antibody
    (¢¡anti-double stranded deoxyribonucleic acid antibod) Ç×ÀÌÁß°¡´Úµð¿£¿¡ÀÌÇ×ü
  • anti-Ro antibody
    Ç׾˿ÀÇ×ü
  • anti-Sm antibody
    Ç׿¡½º¿¥Ç×ü
  • anticardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • concentration-response curve
    ³óµµ¹ÝÀÀ°î¼±
  • conditioned response
    Á¶°Ç¹ÝÀÀ
  • conditioned avoidance response
    Á¶°ÇȸÇǹÝÀÀ
  • conditioned emotional response
    Á¶°Ç°¨Á¤¹ÝÀÀ
  • conditioned fear response
    Á¶°Ç°øÆ÷¹ÝÀÀ
  • consummatory response
    ¼ºÃë¹ÝÀÀ
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
  • frenquency response curve
    Á֯ļö¹ÝÀÀ°î¼±
  • response curve
    ¹ÝÀÀ°î¼±
  • sigmoid dose-response curve
    ±¸ºÒ¼±·®¹ÝÀÀ°î¼±
  • delayed response
    Áö¿¬¹ÝÀÀ
  • dose response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • response decline
    ¹ÝÀÀ°¨¼Ò
  • emotional response
    °¨Á¤¹ÝÀÀ
  • evoked response
    À¯¹ß¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • frenquency response curve
    Á֯ļö ¹ÝÀÀ°î¼±
  • galvanic skin response =GSR
    Àü±âÇǺιÝÀÀ(ï³Ñ¨ù«Ý±Úãëë).
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀ û·Â°Ë»ç
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
  • ideosyncratic drug response
    ƯÀ̼º ¾à¹° ¹ÝÀÀ
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ.
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • immune response suppression
    ¸é¿ª¹ÝÀÀ¾ïÁ¦<--¾ï¾Ð>
  • immune response, secondary
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • immunologic response
    ¸é¿ª¹ÝÀÀ.
  • immunological response
    ¸é¿ªÇÐÀû¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • attachment response
    ¾ÖÂø¹ÝÀÀ
  • attention response
    ÁÖÀÇ·Â ¹ÝÀÀ
  • audiometry, brainstem evoked response =BERA
    ³ú°£À¯¹ß¹ÝÀÀ û·Â°Ë»ç
  • audiometry, evoked response
    À¯¹ß¹ÝÀÀû·Â°Ë»ç
  • audiometry, galvanic skin response =GSR-a.
    ÇǺÎÀü±â¹ÝÀÀ û·Â°Ë»ç
  • audiometry, startle response
    °æ¾Ç¹ÝÀÀû·Â°Ë»ç
  • autoimmune response
    ÀÚ°¡¸é¿ª(í»Ê«Øóæµ) ¹ÝÀÀ(Úãëë)
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • avoidance reaction =a. response
    ȸÇǹÝÀÀ(üÞù­Úãëë)
  • biologic response modifier, BRM
    »ýü¹ÝÀÀÁ¶Àý¹°Áú
  • biologic response modifiers
    »ý¹°ÇÐÀû ¹ÝÀÀÁ¶ÀýÁ¦
  • biological response modifier (BRM)
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶Àý¹°Áú (BRM)
  • brainstem evoked response =BER
    ³ú°£À¯¹ß¹ÝÀÀ
  • brainstem evoked response audiometry =BERA
    ³ú°£À¯¹ß¹ÝÀÀ û·Â°Ë»ç
  • bulbocavernous evoked-response test
    ±¸Çظéü À¯¹ß¹ÝÀÀ°Ë»ç
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Primary ovarian follicle
    ÀÏÂ÷³­Æ÷
    [¿¾ ¿ë¾î] ÀÏÂ÷³­Æ÷
  • Primary cephalic vein
    ÀÏÂ÷¸Ó¸®Á¤¸Æ
    [¿¾ ¿ë¾î] ÀÏÂ÷µÎÁ¤¸Æ
  • Primary capillary network
    ÀÏÂ÷¸ð¼¼Ç÷°ü±×¹°
    [¿¾ ¿ë¾î] ÀÏÂ÷¸ð¼¼Ç÷°ü¸Á
  • Primary abdominal implantation
    ÀÏÂ÷¹è¾ÈÂø»ó
    [¿¾ ¿ë¾î] ÀÏÂ÷Àûº¹ºÎÂø»ó
  • Primary bone
    ÀÏÂ÷»À
    [¿¾ ¿ë¾î] ÀÏÂ÷°ñ
  • Primary osteon
    ÀÏÂ÷»À´ÜÀ§
    [¿¾ ¿ë¾î] ÀÏÂ÷°ñ¿ø
  • Primary bone development
    ÀÏÂ÷»À¹ß»ý
    [¿¾ ¿ë¾î] ÀÏÂ÷°ñ¹ß»ý
  • Primary osteogenic bud
    ÀÏÂ÷»À¹ß»ý½Ï
    [¿¾ ¿ë¾î] ÀÏÂ÷°ñ¹ß»ý·Ú
  • Primary osteogenic bud
    ÀÏÂ÷»À¹ß»ý½Ï
    [¿¾ ¿ë¾î] ÀÏÂ÷°ñÇü¼º¾Æ
  • Primary ossification center
    ÀÏÂ÷»À¹ß»ýÁß½É
    [¿¾ ¿ë¾î] ÀÏÂ÷°ñÈ­Áß½É
  • Primary ossification center [Diaphyseal ossification center]
    ÀÏÂ÷»À¹ß»ýÁ᫐ [»À¸öÅë¹ß»ýÁß½É]
    [¿¾ ¿ë¾î] ÀÏÂ÷°ñÈ­Áß½É
  • Primary bone trabecula
    ÀÏÂ÷»ÀÀܱâµÕ
    [¿¾ ¿ë¾î] ÀÏÂ÷°ñ¼ÒÁÖ
  • Primary trilaminar cortex
    ÀÏÂ÷»ïÃþÆÇ°ÑÁú
    [¿¾ ¿ë¾î] ÀÏÂ÷»ïÃþÆÇÇÇÁú
  • Primary nodule
    ÀÏÂ÷¼ÒÀý
    [¿¾ ¿ë¾î] ÀÏÂ÷¼ÒÀý
  • Primary bud
    ÀÏÂ÷½Ï
    [¿¾ ¿ë¾î] ÀÏÂ÷·Ú
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • memory response
    ±â¾ï´ëÀÀ(ÑÀåãÓßëë)
  • phosphatidylinositol response
    Æ÷½ºÆÄƼµô ´ëÀÀ(Óßëë)
  • PI response
    PI ´ëÀÀ(Óßëë)
  • pleiotypic response
    ´Ù¸é ´ëÀÀ(ÒýØüÓßëë)
  • SOS response
    SOS ´ëÀÀ(Óßëë)
  • staircase response
    °è´Ü ´ëÀÀ(Í­Ó«Óßëë)
  • stringent response
    ¾ö°Ý ´ëÀÀ(åñÌ«Óßëë)
  • tertiary response
    »ïÂ÷´ëÀÀ (ß²ó­Óßëë)
  • primary acidosis
    ¿ø¹ß¼º »êÁõ(ê«Û¡àõß«ñø)
  • primary active transport
    ÀÏÂ÷ ´Éµ¿¼ö¼Û(ìéó­ÒöÔÑâÃáê)
  • primary alkali deficit
    ¿ø¹ß¼º(ê«Û¡àõ) ¾ËÄ®¸®°áÇÌ(ÌÀù¹)
  • primary alkali excess
    ¿ø¹ß¼º(ê«Û¡àõ) ¾ËÄ®¸®°úÀ×(Φí¥)
  • primary alkalosis
    ¿ø¹ß¼º(ê«Û¡àõ) ¾ËÄ®¸®Áõ(ñø)
  • primary amino acid
    ÀÏÂ÷(ìéó­) ¾Æ¹Ì³ë»ê(ß«)
  • primary bile acid
    ÀÏÂ÷ ´ãÁó»ê(ìéó­ÓÅñðß«)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • primary ray
    ÀÏÂ÷¼±
  • primary tuberculosis
    ÀÏÂ÷°áÇÙ(Áõ), Ãʱâ°áÇÙ(Áõ)
  • primary tumor
    ¿ù¹ßÁ¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
PCC Pasteur Culture Collection; percutaneous cecostomy; pheochromocytoma; phosphate carrier compound; pl...
ERA electrical response activity; electroencephalic response audiometry; Electroshock Research Associati...
RR radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati...
AMA against medical advice; alkaline membrane assay; American Management Association; American Medical A...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
I.C.P.C. International Classification of Primary Care
LRC-CPPT Lipid Research Clinics Coronary Primary Prevention Trial
MPC Multiple primary cancer
PHPV Persistent Hyperplastic Primary Vitreous
P Primary
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dose response relationship
    ¹æ»ç¿ë·® ¹ÝÀÀ °ü°è, ¿ë·® ¹ÝÀÀ °ü°è
  • dose-response curve
    ¿ë·® ¹ÝÀÀ °î¼±
  • emotional defense response
    Á¤¼­Àû ¹æ¾î ¹ÝÀÀ
  • evoked response
    À¯¹ß ¹ÝÀÀ
  • humoral immunologic response
    ü¾×¼º ¸é¿ª ¹ÝÀÀ
  • immediate response
    Ãʱ⠹ÝÀÀ
    ¾Ë·¹¸£±â ¹ÝÀÀ°ú °°ÀÌ À¯¹ßÀÎÀÚ¿¡ Á¢ÇÑ ÈÄ, ¸î ÃÊ-¸î ºÐ À̳»¿¡ ÃâÇöÇÏ´Â ¹ÝÀÀ.
  • immune response
    ¸é¿ª ¹ÝÀÀ
  • immunologic response
    ¸é¿ª ¹ÝÀÀ
    Ç׿ø¿¡ ³ëÃâµÊÀ¸·Î½á °³Ã¼ÀÇ ¹ÝÀÀ¼ºÀÌ Æ¯ÀÌÀûÀ¸·Î º¯È­ÇÑ »óÅÂ.
  • learned response
    ÇнÀ ¹ÝÀÀ
    ÇнÀÀ» ½ÃŰ´Â ÀÚ°¡ ÀǵµÇÑ ´ë·Î Çൿ. ¿¹¸¦ µé¸é Á¾ÀÌ ¿ï·Áµµ °³°¡ ħÀ» È긮´Â °ÍÀÌ ÀÖ´Ù.
  • localized protective response
    ±¹¼ÒÀû º¸È£ ¹ÝÀÀ
  • memory immune response
    ¸é¿ªÇÐÀû ±â¾ï ¹ÝÀÀ
  • non-specific response
    ºñƯÀ̼º ¹ÝÀÀ
  • placebo response
    Çö󼼺¸ ¹ÝÀÀ, °¡¾à ¹ÝÀÀ
  • psychophysiologic response
    ½É¸® »ý¸®Àû ¹ÝÀÀ
  • response
    ¹ÝÀÀ, ÀÀ´ä
    Àڱؿ¡ ÀÇÇÏ¿© ÀϾ´Â ÀÛ¿ëÀ̳ª ¿òÁ÷ÀÓ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
response generalisation <biology> The principle that after an organism learns to respond in a particular manner to a stimulus, that stimulus is effective in eliciting similar responses.
(12 Dec 1998)
response hierarchy Alternative reactions or modes of adjustment to a given situation arranged in the probable order of prior effectiveness; e.g., a mother attempting to discipline an unruly child may first request, cajole, then plead, scold, and finally punish; her behaviours can be ordered along a response hierarchy for further monitoring of effectiveness.
(05 Mar 2000)
response rate <oncology> The percentage of patients showing partial or complete response to the given treatment.
(16 Dec 1997)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
complete response <oncology> The disappearance of all clinical evidence of disease. Unfortunately, this does not necessarily mean cure, as microscopic metastases may remain undetected, are likely to regrow and become resistant to treatment.
May also be used in relation to a pathological specimen, where no residual abnormality can be detected in the specimen, in which cas it is referred to as a pathological complete reponse.
Acronym: CR
(16 Mar 1998)
concentration-response curve <pharmacology> This is a graph produced to show the relation between the exposure concentration of a drug (or other chemical) and the degree of response it produces, as measured by the percentage of the exposed population showing a defined, often quantal, effect.
(05 Jan 1998)
conditioned response A response already in an individual's repertoire but which, through repeated pairings with its natural stimulus, has been acquired or conditioned anew to a previously neutral or conditioned stimulus.
See: conditioning.
Compare: unconditioned response.
(05 Mar 2000)
Cushing response A rise in systemic blood pressure when the intracranial pressure acutely increases, usually in excess of 50% of the systolic arterial pressure.
Synonym: Cushing effect, Cushing response.
(05 Mar 2000)
heat-shock response <cell biology> A constellation of responses that occur when an organism is exposed to excessive heat and other environmental stresses. Responses include synthesis of some proteins, repression of other proteins, and expression of new proteins.
(12 Dec 1998)
heat-shock response element <cell biology, protein> The nucleotide sequence, CNNGAANNTCCNG, which is in the promoter region of the heat-shock genes. When the animal is exposed to certain types of stress such as a sudden rise in temperature, the first thing that happens to activate these genes is the binding of the HSE by a transcriptional enhancer protein.
(09 Oct 1997)
Henry-Gauer response Inhibition of antidiuretic hormone secretion due to a rise in atrial pressure which stimulates atrial stretch receptors.
(05 Mar 2000)
satiety response Behavioural response associated with the achieving of gratification.
(12 Dec 1998)
psychogalvanic response A change in electrical resistance of the skin, occurring in emotion and in certain other conditions.
(12 Dec 1998)
secondary immune response The response of the immune system to the second or subsequent occasion on which it encounters a specific antigen.
(18 Nov 1997)
humoral immune response <immunology> Those immune responses mediated by antibody.
(06 Mar 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • primary
    Áß¿äÇÑ
  • closed primary
    Á¦ÇÑ ¿¹ºñ ¼±°Å(´ç¿ø À¯ÀÚ°ÝÀÚ¸¸ÀÌ ÅõÇ¥ÇÏ´Â Èĺ¸ÀÚ ¼±°Å)
  • dircct primary
    Á÷Á¢ ¿¹¼±
  • indirect primary
    (¹Ì)°£Á¢ ¿¹ºñ ¼±°Å
  • open primary
    °ø°³ ¿¹¼± ´ëȸ
  • presidential primary
    (°¢ Á¤´çÀÇ)´ëÅë·É ¼±°ÅÀÎ ¿¹¼±È¸
  • primary
    ÃÖÃÊÀÇ;¿ø½ÃÀûÀÎ;¼öÀ§ÀÇ;ÁÖ¿äÇÑ;º»·¡ÀÇ;±Ùº»ÀÇ;Ãʺ¸ÀÇ;Á¦ 1±âÀÇ;1Â÷ÀÇ-Á¦ 1À§ÀÇ »ç¹°;¿ø»ö;ÀÏÂ÷¾î(¸í»ç »ó´ç ¾î±¸);´ëÅë·É Èĺ¸ ¿¹ºñ ¼±°Å
  • primary accent
    Á¦ ÀÏÀÇ ¾Ç¼¾Æ®
  • primary assembly
    ¿¹¼± ´ëȸ;»çÀü ÇùÀÇȸ
  • primary atypical pneumonia
    1Â÷¼º ºñÁ¤Çü Æó·Å
  • primary care
    ÀÏÂ÷ ÀÇ·á(ÀÀ±Þ Ä¡·á µî ÁÖ°ÅÁö¿¡¼­ ÇàÇÏ´Â Ãʱâ ÀÇ·á)
  • primary cell
    1Â÷ ÀüÁö
  • primary coil
    1Â÷ ÄÚÀÏ
  • primary colors
    ¿ø»ö(»¡°­,³ë¶û,ÆÄ¶û)
  • primary consumer
    Á¦1Â÷ ¼ÒºñÀÚ(ÃÊ½Ä µ¿¹°)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á